[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elective-cesarean-delivery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elective-cesarean-delivery":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100624390","development-of-a-patient-centered-assessment-tool-for-pain-during-cesarean-delivery-100624390",false,"NCT07409012","Development of a Patient-Centered Assessment Tool for Pain During Cesarean Delivery","Pain During Cesarean Delivery: a Patient-Centered Assessment Tool Developed With Mixed Methods","Inclusion Criteria:\n\n* Signed informed consent\n* Age \\> 18 years\n* Proficient in German or Swiss German\n* Elective cesarean delivery under neuraxial anesthesia in last 48-72 hours\n* Delivery of an healthy infant of at least 35+1 weeks of gestation\n\nExclusion Criteria:\n\n* Known fetal abnormalities or neonatal death\n* Admission of the neonate to the ICU\n* Severe postpartum hemorrhage of \\>1000ml blood loss\n* Preeclampsia\n* Current psychiatric disease, e.g. schizophrenia, personality disorders\n* Substance abuse\n* Chronic pain disease",true,"FEMALE","18 Years",{"count":20,"type":21},15,"ESTIMATED","OBSERVATIONAL","This study aims to develop a standardized tool to assess intraoperative pain during cesarean delivery under neuroaxial anesthesia. The tool will draw on existing scientific literature, expert clinical opinion and the experiences of patients who have recently undergone caesarean delivery. Experts from multiple disciplines will participate in a structured consensus process (Delphi process) to identify and refine key assessment items. Patient interviews will be conducted to ensure that the tool reflects patient priorities and experiences.",[25],"Elective Cesarean Delivery","RECRUITING","2026-04-23",{"date":29,"type":30},"2026-04-29","ACTUAL",{"date":32,"type":21},"2026-05",{"date":34,"type":21},"2026-08",{"name":36,"class":37},"University Hospital, Basel, Switzerland","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100626633","maternal-satisfaction-after-spinal-anesthesia-for-cesarean-delivery-100626633","NCT07438171","Maternal Satisfaction After Spinal Anesthesia for Cesarean Delivery","Maternal Satisfaction Following Different Spinal Anesthesia Regimens for Elective Cesarean Delivery: a Prospective Observational Study","Inclusion Criteria: Parturients for elective cesarean delivery, ASA, status II and III, age between 18 and 45 years, singleton pregnancy, able to provide inform consent. -\n\nExclusion Criteria: Refuse to participate in the study, spinal anesthesia refused, known drug allergies to drugs included in the study, multiple pregnancy, preterm gestation, skin lesion at the beck, severe maternal comorbidities, chronic opioid use and chronic pain. -","45 Years",{"count":48,"type":21},200,"The goal of this observational study is to evaluate the impact of four different spinal anesthesia regimens on maternal satisfaction following cesarean delivery.\n\nThe main questions this study aims to answer are:\n\n* Primary outcome: Patient satisfaction with the provided analgesia during the first 24 hours postoperatively.\n* Secondary outcome: The need for rescue analgesics. Participants will complete a specially designed questionnaire 24 hours after cesarean delivery.",[51,25],"Parturients",[53,54,55,56],"Maternal satisfaction","Spinal anesthesia","cesarean delivery","postcesarean analgesia","NOT_YET_RECRUITING","2026-02-22",{"date":60,"type":30},"2026-02-27",{"date":62,"type":21},"2026-03-02",{"date":64,"type":21},"2026-09-01",{"name":66,"class":37},"University of Novi Sad",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100534201","administration-of-calcium-gluconate-for-the-reduction-of-blood-loss-during-elective-cesarean-delivery-100534201","NCT06235749","Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery","Inclusion Criteria:\n\n\\- Elective Cesarean Delivery, at Gestational age of 35 weeks or more.\n\nExclusion Criteria:\n\n* Age younger than 18 years old.\n* Patients treated with calcium channel blockers.\n* Chronic renal failure and hyperphosphatemia.\n* Sarcoidosis.\n* Hypocalcemia (ionized Ca\\\u003C1 mmol\u002FL) or hypercalcemia (ionized Ca\\> 1.3 mmol\u002FL) before the surgery.\n* Any QT abnormalities as evident by ECG before Calcium Gluconate administrations or any known conduction abnormality.",{"count":74,"type":21},1180,"INTERVENTIONAL",[77],"NA","Postpartum hemorrhage (PPH) is the leading cause of death related to pregnancy. PPH can lead to blood transfusion, disseminated intravascular coagulation (DIC), hysterectomy, or death. The prophylactic administration of uterotonic agents as part of an active management of the third stage of labor has been proven to reduce rates of PPH. However, even with these treatments, PPH rate is still relatively high, and puts women at risk of heavy bleeding and death.\n\nCalcium is a key component in the coagulation cascade and known as factor IV. It has a role in platelet activation, and it is an important co-factor for the activation of factors II and There is a concentration-dependent effect of hypocalcemia on in vitro clot strength in patients at risk of bleeding. Calcium gluconate is the calcium salt of gluconic acid, and it has a relatively strong safety profile.\n\nHypocalcemia is a poor prognostic factor in actively bleeding patients. Calcium has a positive inotropic effect both on skeletal muscle and smooth muscle. The inotropic effect doesn't skip the myometrium, and it is well-established that hypocalcemia can impair myometrial contractility. As so, calcium channel blockers are prescribed as a tocolytic drug and calcium gluconate should be considered as adjuvant therapy for treating PPH duo to atony, in case of prolonged tocolytic or magnesium sulfate use prior to delivery. Studies have already shown an association between low ionized calcium levels and the risk for severe bleeding. In a pilot randomized controlled trial of patients with risk factors for uterine atony, calcium was shown to reduce uterine atony compared to placebo. However, current studies have small sample size and are limited to a high-risk population. There are no recommendations in current guidelines for monitoring calcium levels or prescribing calcium as a prophylactic measure for the third stage of labor, despite atony and coagulopathy being significant causes of PPH.\n\nHYPOTHESIS: Administration of Calcium Gluconate at the third stage of elective Cesarean delivery will decrease the rates of blood loss during and after the surgery by reducing the rates of uterine atony and development of coagulopathy, thus has the potential of reducing the incidence of PPH and its complications without severe side effects.",[25],"2025-01-27",{"date":82,"type":30},"2025-01-28",{"date":84,"type":30},"2023-11-14",{"date":86,"type":21},"2026-12-31",{"name":88,"class":37},"Rambam Health Care Campus",4]